SCHEMBL4507733

SCHEMBL4507733

COc1ccc(-c2sc(CNS(=O)(=O)c3cc(C)oc3C(F)(F)F)cc2-c2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.42
MAPT P10636 3/20 0.41
NR3C1 P04150 1/20 0.39
PGR P06401 1/20 0.39
EP300 Q09472 1/20 0.38
TP53 P04637 2/20 0.37
KMT2A Q03164 3/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
CNR2 P34972 2/20 0.35
HSD17B10 Q99714 1/20 0.35
LMNA P02545 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489017 0.87 NR3C1 (0.38) CNR1MAPTNR3C1PGREP300
SCHEMBL4499592 0.85 CNR2 (0.41) CNR1MAPTNR3C1PGRKMT2A
SCHEMBL4488378 0.85 MAPT (0.52) CNR1MAPTNR3C1PGREP300
SCHEMBL4480858 0.82 KMT2A (0.41) CNR1MAPTNR3C1PGREP300
SCHEMBL4494987 0.82 ALDH1A1 (0.47) CNR1MAPTTP53KMT2ASMN1; SMN2
SCHEMBL4497264 0.81 ALDH1A1 (0.44) MAPTPGRKMT2AALDH1A1LMNA
SCHEMBL4508001 0.81 CNR1 (0.43) CNR1MAPTEP300KMT2ATSHR
SCHEMBL4508447 0.81 KMT2A (0.45) CNR1MAPTEP300TP53KMT2A
SCHEMBL4506429 0.81 ALDH1A1 (0.43) CNR1MAPTEP300TP53KMT2A
SCHEMBL4496378 0.81 MAPT (0.51) CNR1MAPTNR3C1PGRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589120-B2 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-15 US claimed
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-12-13 US claimed
US-7589120-B2 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-15 US disclosed
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-12-13 US disclosed
EP-1841754-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-10-10 EP disclosed
WO-2006077320-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION TPMT, TXNRD2, ARG2 CNR1 60/4885MAPT 4238/4885NR3C1 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.